Onychomycosis

For additional information, please contact: Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se Mark Beveridge, VP Finance, Phone: +46 76 805 82 88, e-mail: mark.beveridge@mobergpharma.se About this information The information was submitted for publication, through the agency of the contact person set out above, on April 11, 2025, at 8.00 am CET. About Moberg Pharma, www.mobergpharma.com Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries. MOB-015 is sold in Sweden and Norway under the brand name Terclara® and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).

Almirall has announced that it will be hosting the 16th edition of its Skin Academy, a conference that encourages collaboration and the development of new methods and solutions in the field of dermatology. The event brings together a broad range of experts and clinicians from across the world, Almirall said, with this year’s offering featuring a programme aimed at sharing scientific knowledge on skin diseases, their treatment and clinical best practice. The company’s chief medical officer, Volker Koscielny, said: “This is the 16th edition of the Skin Academy, and we are proud to continue to provide a leading platform for exchange and advancement in medical dermatology. “Skin Academy fosters collaboration and co-creation of innovative approaches and solutions that help the medical dermatology community to better respond to the unmet needs of millions of people living with these conditions.” Among the diseases covered by this year’s programme is actinic keratosis (AK), the most common precancerous skin condition, characterised by rough, scaly patches of skin that commonly develop on the most exposed areas of the body. Skin Academy will aim to highlight the importance of early treatment in AK to prevent its progression to squamous cell carcinoma, with experts set to cover advancements in treatment, real-world evidence, as well as the importance of patient satisfaction in treatment outcomes. Psoriasis, an immune-mediated disease that causes inflammation in the body, will be a key focus area of this year’s event and will be addressed in sessions dedicated to biologic treatments. Atopic dermatitis, the most common form of eczema, will be another focal point, with experts offering insights into its pathophysiology, the role of IL-13 and the importance of advanced treatment protocol. Topics on other dermatological conditions, including androgenetic alopecia, onychomycosis and chronic spontaneous urticaria, will also be included in the programme. Ulrich Mrowietz, the Psoriasis Center at the University Medical Center Schleswig-Holstein, Campus Kiel, said: “Deep collaboration across experts is essential for advancing medical dermatology and providing better treatment outcomes for patients. “Almirall’s Skin Academy provides a unique platform for practitioners to explore latest scientific advances, clinical practice and discuss a broad range of skin diseases, with an emphasis on holistic, personalised patient care and well-being.”

As announced on December 18, 2024, Moberg Pharma has qualified a new terbinafine supplier, which was a prerequisite for the launch in Norway to take place in 2025. Moberg Pharma has already secured enough terbinafine for initial launch, and with the new terbinafine manufacturer, the company is now confidently moving forward with the rollout of Terclara in Norway. The experience from Sweden gives us strong confidence in the Norwegian market, and the launch of Terclara® in Norway follows the same approach as in Sweden. The first deliveries to pharmacies are expected in February, followed by targeted information campaigns for pharmacy staff and healthcare professionals. In parallel, consumer marketing will intensify ahead of the peak season, when the demand for nail fungus treatment traditionally increases. "The launch of Terclara® in Norway is a milestone for our expansion in the European market. Allderma has proven to be a highly capable partner that has delivered strong results in Sweden. We have great confidence in their ability to replicate this success in the Norwegian market," says Anna Ljung, CEO of Moberg Pharma AB. "We are proud to now be able to start the launch in Norway. The experience from Sweden has been invaluable in ensuring a successful launch and we are confident that the product will secure a strong position in the Norwegian market", says Mimmi Frölén, CEO of Allderma AB. For additional information, please contact: Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se About this information The information was submitted for publication, through the agency of the contact person set out above, on February 3, 2025, at 8.00 am CET. About Moberg Pharma, www.mobergpharma.com Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries. MOB-015 is sold in Sweden under the brand name Terclara® and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB). About Allderma Pharmaceuticals, www.allderma.se Allderma Pharmaceuticals is a Swedish pharmaceutical company that since 2001 develops, sells and markets over the counter and self-care products. The range spans a number of different treatment areas, with a focus and expertise in dermatology. Founder Hans Svartholm started Allderma after working in the pharmaceutical industry for many years. The idea was simple and still applies it should be easy to find an effective and safe product for the most common skin problems. Allderma emphasis and invests in information for healthcare providers, pharmacists, doctors and consumers. Product specialists work continuously to be a spear head in research and innovation within dermatology. Allderma has been part of 3iM Invest AB's investment area Consumer Healthcare since 2020.